Storia in 2 fonti

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo5 g fa

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.